Mr. Soonkap Hahn has founded six start-ups: Novatrix, Inc. in 1993, Biocept, Inc. in 1997, Avicule, Inc. in 2004, JCSS Biomedical, Inc. in 2005, Curexo USA in 2006 and Postsurgical Therapeutics, Inc. in 2014. He served as Chief Technical Officer and/or Chief Executive Officer and organized each of these companies. These companies raised a total of over $300 million through private investors and venture capital firms. He obtained proprietary technologies by internal technology/product development or through license agreements. His technical expertise includes drug delivery system/drug development and cancer diagnostics. In 2006, he sold the assets of three of these companies (Novatrix, Avicule and JCSS) to Curexo, Inc. in Korea and in 2019 three other projects to Upex-Med in Korea. Biocept (liquid biopsy company) became a public company in 2014 (stock symbol “BIOC”). Mr. Hahn has extensive experiences in M & A and license agreements. He received his Ph.D. in organic chemistry from Ohio State University in 1985 and performed postdoctoral research at Stanford University with Professor Carl Djerassi in 1986. He has 14 issued US patents and 8 pending patent applications.

Mr. Jason Lee has been a seasoned and experienced corporate executive over 20 years with combined expertise in financial accounting, administration, operations, risk management and strategic planning. He took CFO position at Novatrix, Inc., Avicule, Inc. and JCSS Biomedical, Inc. in 2006 until their successful closings. He currently acts as CFO at Postsurgical Therapeutics, Inc. since 2014. His main responsibilities are covering administrative, accounting and finance functions. His previous job experience was with banking industry and he held various executive positions. He holds BA and Master degrees from Seoul National University and MBA degree from Anderson School, UCLA.

Mr. Rey Magaña, is a serial entrepreneur with over 25 years of experience in preclinical and clinical R&D operations, business development, and marketing. He has worked in the pharmaceutical, biotechnology, medical device, and nutritional industries. He has managed projects and R&D programs in cancer, diabetes, cardiovascular, and other therapeutic areas. He was co-inventor and was part of the team that pioneered Extracellular vesicle and Exosome nucleic acid technologies for applications in molecular diagnostics, drug delivery, and therapeutics. He cofounded Proxy Life Science Holdings, a biotechnology company organized to develop those technologies and held the positions of Vice President and Director of Business Development. He also cofounded Perry Scientific, a contract research organization specializing in pre-clinical research services supporting early-stage pharmaceutical, biopharmaceutical, and medical device companies. The company catered to both emerging and established blue-chip companies. Mr. Magana was responsible for strategy, business development, and operations. He held the title of VP and Chief Operations Officer. His key duty was the development and delivery of custom research services including efficacy, pharmacokinetics, and safety studies in areas as diverse as oncology, metabolic diseases, cardiology, dermatology, immunology, drug delivery, cosmetics, nutraceuticals, and medical devices. He co-founded NutraClinical Inc. a near-shore clinical research organization delivering clinical trial services for the nutritional industry. His primary role was in business development and contract negotiations.

Mr. Kenneth Brown's career has focused on business development positions in pharmaceutical and biotechnology companies for licensing in and out of technology and products. Early in his career, he worked for “'traditional” pharmaceutical companies: six years with GD Searle & Company (now part of Pfizer) and 10 years with Syntex Corporation (now part of Hoffmann-LaRoche). For the last 25 years, he has held senior business development positions in biopharmaceutical companies with novel Drug Discovery and development technology, drug delivery technology and novel Diagnostics. Several agreements completed include outlicensing of transcription factors for the treatment of diabetes and potential use for treatment of cancer, and drug delivery technology. He established numerous collaborations, including material transfer agreement with universities and not for profit research organizations. He has authored 20 articles for industry publications on topics such as drug discovery and development, drug delivery technology, regulatory procedures and market opportunities. His expertise includes the cardiovascular, metabolic disorders and reproductive therapy areas, and drug delivery technology for all therapeutic areas. He received Bachelor and Master of Science degrees in biochemistry and an MBA, all from the University of Chicago.